8EUR
Co-crystal structure of Chaetomium glucosidase with compound 26
This is a non-PDB format compatible entry.
Summary for 8EUR
Entry DOI | 10.2210/pdb8eur/pdb |
Descriptor | Chaetomium alpha glucosidase, 2-{[2-nitro-4-(triazan-1-yl)phenyl]amino}ethyl (2-{[(1S,2S,3R,4S,5S)-2,3,4,5-tetrahydroxy-5-(hydroxymethyl)cyclohexyl]amino}ethyl)carbamate, GLYCEROL, ... (6 entities in total) |
Functional Keywords | alpha glucosidase i, hydrolase, inhibitor complex, hydrolase-inhibitor complex, hydrolase/inhibitor |
Biological source | Thermochaetoides thermophila |
Total number of polymer chains | 2 |
Total formula weight | 188876.58 |
Authors | Karade, S.S.,Mariuzza, R.A. (deposition date: 2022-10-19, release date: 2023-02-22, Last modification date: 2023-10-25) |
Primary citation | Karade, S.S.,Franco, E.J.,Rojas, A.C.,Hanrahan, K.C.,Kolesnikov, A.,Yu, W.,MacKerell Jr., A.D.,Hill, D.C.,Weber, D.J.,Brown, A.N.,Treston, A.M.,Mariuzza, R.A. Structure-Based Design of Potent Iminosugar Inhibitors of Endoplasmic Reticulum alpha-Glucosidase I with Anti-SARS-CoV-2 Activity. J.Med.Chem., 66:2744-2760, 2023 Cited by PubMed Abstract: Enveloped viruses depend on the host endoplasmic reticulum (ER) quality control (QC) machinery for proper glycoprotein folding. The endoplasmic reticulum quality control (ERQC) enzyme α-glucosidase I (α-GluI) is an attractive target for developing broad-spectrum antivirals. We synthesized 28 inhibitors designed to interact with all four subsites of the α-GluI active site. These inhibitors are derivatives of the iminosugars 1-deoxynojirimycin (1-DNJ) and valiolamine. Crystal structures of ER α-GluI bound to 25 1-DNJ and three valiolamine derivatives revealed the basis for inhibitory potency. We established the structure-activity relationship (SAR) and used the Site Identification by Ligand Competitive Saturation (SILCS) method to develop a model for predicting α-GluI inhibition. We screened the compounds against SARS-CoV-2 to identify those with greater antiviral activity than the benchmark α-glucosidase inhibitor UV-4. These host-targeting compounds are candidates for investigation in animal models of SARS-CoV-2 and for testing against other viruses that rely on ERQC for correct glycoprotein folding. PubMed: 36762932DOI: 10.1021/acs.jmedchem.2c01750 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (2.61 Å) |
Structure validation
Download full validation report